Siltuximab

Medical uses

Siltuximab is indicated for the treatment of people with multicentric Castleman's disease who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Side effects

The common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection.

Drug interactions

Siltuximab may increase CYP450 activity leading to increased metabolism of drugs that are CYP450 substrates.

Mechanism of action

Siltuximab is a chimeric monoclonal antibody that binds to interleukin-6 (IL-6), preventing binding to soluble and membrane bound interleukin-6 receptors. Siltuximab interferes with IL-6 mediated growth of B-lymphocytes and plasma cells, secretion of vascular endothelial growth factor (VEGF) and autoimmune phenomena.

History

Siltuximab demonstrated efficacy and safety in people with idiopathic multicentric Castleman disease, found research formally published in 2016. Treatment results with siltuximab in B-cell non-Hodgkin's lymphoma are inferior to those obtained in multicentric Castleman disease.

The approval by the US FDA was based on an international, multicenter, randomized (2:1), phase II study comparing every three-week intravenous infusions of siltuximab and best supportive care to placebo and best supportive care. The trial enrolled 79 participants and randomly allocated 53 participants to the siltuximab arm plus best supportive care and 26 participants randomized to the placebo arm plus best supportive care. Siltuximab was administered every three weeks as an intravenous infusion at a dose of 11 mg/kg.

Research

Siltuximab has been investigated for the treatment of neoplastic diseases: metastatic renal cell cancer, prostate cancer, other types of cancer, and for Castleman's disease.

Siltuximab has been evaluated in the treatment of ovarian cancer, however the efficacy for this cancer is debatable. In addition, siltuximab has been evaluated for multiple myeloma, but there was an insignificant increase in response rates.

References

References

1. (21 June 2022). "Prescription medicines: registration of new chemical entities in Australia, 2015".
2. (21 February 2024). "Sylvant- siltuximab injection, powder, for solution".
3. (30 November 2007). "Sylvant EPAR".
4. (2009). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 62". WHO Drug Information.
5. (23 April 2014). "Siltuximab".
6. (28 September 2015). "Sylvant (siltuximab)".
7. (2016). "Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease". Immunotherapy.
8. (December 2016). "Review of siltuximab in the treatment of multicentric Castleman's disease". Therapeutic Advances in Hematology.
9. (March 2017). "Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma". Expert Opinion on Investigational Drugs.
10. (January 2017). "TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis". Cytokine.
11. (October 2010). "A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer". British Journal of Cancer.
12. (September 2011). "The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study". The Prostate.
13. "Siltuximab". ClinicalTrials.gov.
14. (August 2010). "Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease". Journal of Clinical Oncology.
15. (October 2013). "First IL-6-blocking drug nears approval for rare blood disorder". Nature Medicine.
16. (2018). "Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities". Current Medicinal Chemistry.
17. (June 2016). "Novel agents in the treatment of multiple myeloma: a review about the future". Journal of Hematology & Oncology.